A team of pharmaceutical researchers at Novartis Biomedical Research, working with an international team of associates, has ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

BOSTON, April 03, 2025--eClinical Solutions LLC, a global provider of digital clinical software and services, today unveiled ...

Research reveals how specific sleep stages protect brain vulnerable to Alzheimer's, offering hope through simple lifestyle ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier ...

Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced the successful completion of the Phase III clinical study ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced it will present data from the Phase 1 dose ...

Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...